Core Insights - The company, Hongbo Pharmaceutical (301230.SZ), reported a total revenue of 353 million yuan for the first half of 2025, marking an increase of 86.97 million yuan compared to the same period last year, representing a year-on-year growth of 32.73% [1] - The net profit attributable to shareholders reached 24.76 million yuan, an increase of 8.78 million yuan from the previous year, reflecting a year-on-year increase of 54.99% [1] - The net cash inflow from operating activities was 39.43 million yuan, up by 61.02 million yuan compared to the same period last year [1] Financial Ratios - The company's latest debt-to-asset ratio stands at 21.85%, ranking 14th among disclosed peers, a decrease of 2.83 percentage points from the same period last year [3] - The latest gross profit margin is 27.93%, an increase of 4.15 percentage points year-on-year [3] - The return on equity (ROE) is 2.34%, ranking 18th among peers, with an increase of 0.83 percentage points from the previous year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.18 yuan, ranking 16th among peers, with an increase of 0.07 yuan, representing a year-on-year growth of 63.64% [3] - The total asset turnover ratio is 0.26 times, ranking 9th among peers, with an increase of 0.08 times, achieving a consecutive increase over two years, and a year-on-year growth of 43.89% [3] - The inventory turnover ratio is 3.74 times, ranking 14th among peers, with an increase of 0.72 times, also achieving a consecutive increase over two years, and a year-on-year growth of 23.67% [3] Shareholder Structure - The number of shareholders is 16,300, with the top ten shareholders holding a total of 83.60 million shares, accounting for 59.89% of the total share capital [3] - The largest shareholder is Hongbo Zhiyuan (Hong Kong) Pharmaceutical Technology Co., Ltd., holding 27.70% of the shares [3]
泓博医药(301230.SZ)：2025年中报净利润为2476.14万元、较去年同期上涨54.99%